RPG Life Sciences is currently trading at Rs. 69.00, up by 0.20 points or 0.29% from its previous closing of Rs. 68.80 on the BSE.
The scrip opened at Rs. 71.85 and has touched a high and low of Rs. 71.85 and Rs. 69.00 respectively.
The BSE group 'B' stock of face value Rs. 8 has touched a 52 week high of Rs. 92.75 on 03-Aug-2011 and a 52 week low of Rs. 57.00 on 21-Dec-2011.
Last one week high and low of the scrip stood at Rs. 74.95 and Rs. 67.50 respectively. The current market cap of the company is Rs. 114.00 crore.
The promoters holding in the company stood at 52.56% while Institutions and Non-Institutions held 2.90% and 44.54% respectively.
RPG Life Sciences has failed to receive EU GMP certification for its API facility at Navi Mumbai in Maharashtra post inspection of relevant authorities citing certain deficiencies. In this regards, the company has received communication from the Ministry of Social and Family Affairs, Health and Consumer Protection, Hamburg, Germany for not granting the certification.
This will have adverse impact on export business of the company. The company has taken immediate remedial measures, is reviewing all the issue raised by the said health authority and is working towards resolving them in a time bound manner.
Further, the company continues to hold a valid WHO GMP and TGA, Australia certification for its facilities.
RPG Lifesciences (RPGLS), part of the RPG group, is a pharmaceutical company, engaged in manufacturing of Synthetic APIs, Biotech APIs and Formulations under its own brand name and contract manufacturing for large pharma companies. The company’s manufacturing facilities are located at Ankleshwar, Gujarat and Thane, Maharashtra.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.75 |
| Dr. Reddys Lab | 1272.10 |
| Cipla | 1391.70 |
| Zydus Lifesciences | 1104.60 |
| Lupin | 2284.00 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: